Fig. 4.

Effects of systemic treatment of quercetin on baseline locomotor activity and MK-801-induced locomotor hyperactivity. (A) Behavioral protocol. (B) Sample locomotion traces of mice after injection (i.p.) with control vehicle (grey) or quercetin (50 mg/10 ml per kg, light blue), following a 30-min habituation in the open field. (C) The total distance traveled during each 5-min interval. n = 17–19 for each group. N.S., not significant difference, ^###p < .001, vehicle vs. quercetin, two way repeated-measures ANOVA. (D) The total distance of vehicle- and quercetin-treated mice during the first 30-min habituation session and the following 30-min test session, respectively. n = 17–19 for each group. N.S., not significant difference, ^###p < .001, vehicle vs. quercetin, unpaired Student's t-test. (E) Sample locomotion traces of vehicle- or quercetin-treated mice, each of which were then subdivided into two groups and treated with saline or MK-801 (in saline, 0.2 mg/10 ml per kg mice), respectively. (F) The total distance of vehicle- or quercetin-treated mice followed by injection (i.p.) of saline or MK-801 traveled during each 5-min interval. n = 8–10 for each group. ^⁎⁎⁎p < .001, saline vs. MK-801; N.S., not significant difference, ^###p < .001, vehicle vs. quercetin, two way repeated-measures ANOVA. (G) The total distance in the 30-min session of mice followed by saline or MK-801 injection. n = 8–10 for each group. ^⁎⁎⁎p < .001, saline vs. MK-801; N.S., not significant difference, ^###p < .001, vehicle vs. quercetin, unpaired Student's t-test. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)